Patent application number | Description | Published |
20080269204 | Compounds and Methods of Use Thereof - Benzolactam boronic acid compounds and pharmaceutical formulations are described along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof. | 10-30-2008 |
20080319044 | Compounds and Methods of Use Thereof - Indole boronic acid compounds, and analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof. | 12-25-2008 |
20090005344 | Compounds and Methods of Use Thereof - Imidazole and benzimidazole boronic acid compounds, analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof. | 01-01-2009 |
20090264384 | INDOLE, BENZIMIDAZOLE, AND BENZOLACTAM BORONIC ACID COMPOUNDS, ANALOGS THEREOF AND METHODS OF USE THEREOF - Benzimidazole, indole and benzolactam boronic acid compounds, analogs thereof, and pharmaceutical formulations are described, along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-α) in a subject in need thereof. | 10-22-2009 |
20100120740 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE - The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective. | 05-13-2010 |
20110034434 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE - The invention relates to prodrugs of fused heterocyclic inhibitors of D-amino oxidase (DAAO) and methods of treating diseases and conditions, wherein modulation of D-amino acid oxidase activity, D-serine levels, D-serine oxidative products and NMDA receptor activity in the nervous system of a mammalian subject is effective. | 02-10-2011 |
Patent application number | Description | Published |
20080200924 | METHODS FOR MINIMALLY INVASIVE, NON-PERMANENT OCCLUSION OF A UTERINE ARTERY - A method of treating a uterine disorder comprising non-permanently occluding a uterine artery with a resorbable embolic mass for a therapeutically effective time period. The occluding step includes selectively positioning the resorbable embolic mass within the uterine artery, and monitoring positioning of the resorbable embolic mass at a desired location within the uterine artery. The monitoring step may include using ultrasound or magnetic resonance imaging (MRI) for positioning the resorbable embolic mass at the desired location within the uterine artery. The resorbable embolic mass may be swellable and may be formed of a polymeric material selected from the group consisting of polylactic acid, polyglycolic acid, polyethylene glycol, or copolymers thereof. | 08-21-2008 |
20080287828 | Biopsy anchor device with cutter - A device for accessing and for isolating a desired site within a patient's body, and for obtaining a body of tissue from a patient at the site that includes an electrosurgical cutting electrode near the distal tip of a shaft, an anchoring mechanism and an electrosurgical side-cutting device. Methods are provided for accessing a target site within a patient's body, anchoring a body of tissue at the site, and isolating the body of tissue, at the site. The method may be performed for a surgical biopsy or lumpectomy at the target site within a patient's body. | 11-20-2008 |
20090131825 | Imageable biopsy site marker - A biopsy site marker having at least one small marker body or pellet of bioresorbable material such as gelatin, collagen, polylactic acid, polyglycolic acid which has a radiopaque object, preferably with a non-biological configuration. The at least one bioresorbable body or pellet with a radiopaque object is deposited into the biopsy site, by a delivery device that includes an elongated tubular body with a piston slidable within the tubular body. One end of the tube is placed into the biopsy site. At least one but preferably several marker bodies or pellets are deposited sequentially into the biopsy site through the tube. At least the bioresorbable materials of the detectable markers remain present in sufficient quantity to permit detection and location of the biopsy site at a first time point (e.g., 2 weeks) after introduction but clear from the biopsy site or otherwise do not interfere with imaging of tissues adjacent the biopsy site at a second time point (e.g., 5-7 months) after introduction. | 05-21-2009 |
20100198059 | REMOTELY ACTIVATED MARKER - A biopsy site marker having at least one small marker body or pellet of bioresorbable material such as gelatin, collagen, polylactic acid, polyglycolic acid which has a radiopaque object, preferably with a non-biological configuration. The at least one bioresorbable body or pellet with a radiopaque object is deposited into the biopsy site, by a delivery device that includes an elongated tubular body with a piston slidable within the tubular body. One end of the tube is placed into the biopsy site. At least one but preferably several marker bodies or pellets are deposited sequentially into the biopsy site through the tube. At least the bioresorbable materials of the detectable markers remain present in sufficient quantity to permit detection and location of the biopsy site at a first time point (e.g., 2 weeks) after introduction but clear from the biopsy site or otherwise do not interfere with imaging of tissues adjacent the biopsy site at a second time point (e.g., 5-7 months) after introduction. | 08-05-2010 |
20120277626 | METHODS AND APPARATUS FOR SECURING MEDICAL INSTRUMENTS TO DESIRED LOCATIONS IN A PATIENT'S BODY - A medical device for localization of tissue at a target site in a patient's body includes a tube having a distal end, a proximal end, and a longitudinal axis. The medical device is configured for placement of the distal end at the target site. A fixation device is disposed on the distal end. The affixation device is configured to mechanically fix the distal end of the medical device to tissue at the target site. | 11-01-2012 |